Vaccine-induced immune thrombotic thrombocytopenia (VITT) after SARS-CoV-2 vaccination: Two cases from Germany with unusual presentation
Standard
Vaccine-induced immune thrombotic thrombocytopenia (VITT) after SARS-CoV-2 vaccination: Two cases from Germany with unusual presentation. / Edmonds, Rhea; Schönborn, Linda; Habben, Sunke; Paparoupa, Maria; Greinacher, Andreas; Schuppert, Frank.
In: CLIN CASE REP, Vol. 11, No. 1, 01.2023, p. e6883.Research output: SCORING: Contribution to journal › Case report › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Vaccine-induced immune thrombotic thrombocytopenia (VITT) after SARS-CoV-2 vaccination: Two cases from Germany with unusual presentation
AU - Edmonds, Rhea
AU - Schönborn, Linda
AU - Habben, Sunke
AU - Paparoupa, Maria
AU - Greinacher, Andreas
AU - Schuppert, Frank
N1 - © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
PY - 2023/1
Y1 - 2023/1
N2 - Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare clinical condition that has emerged during the mass immunization against SARS-CoV-2. Reports indicate that VITT may also be induced by other vaccines, such as the human papillomavirus vaccine, or occur independently of vaccination. Its recognition requires a high index of suspicion, especially in patients presenting with thrombocytopenia and thrombosis several days after vaccination with an adenoviral vector-based vaccine against SARS-CoV-2. Bleeding manifestations do not exclude VITT, as initially assumed. It is of great importance to perform the appropriate diagnostic tests early in the course of the disease, as false-negative results may occur and many aspects of VITT are not fully understood. These two cases from Germany demonstrate unusual presentations of VITT.
AB - Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare clinical condition that has emerged during the mass immunization against SARS-CoV-2. Reports indicate that VITT may also be induced by other vaccines, such as the human papillomavirus vaccine, or occur independently of vaccination. Its recognition requires a high index of suspicion, especially in patients presenting with thrombocytopenia and thrombosis several days after vaccination with an adenoviral vector-based vaccine against SARS-CoV-2. Bleeding manifestations do not exclude VITT, as initially assumed. It is of great importance to perform the appropriate diagnostic tests early in the course of the disease, as false-negative results may occur and many aspects of VITT are not fully understood. These two cases from Germany demonstrate unusual presentations of VITT.
U2 - 10.1002/ccr3.6883
DO - 10.1002/ccr3.6883
M3 - Case report
C2 - 36698527
VL - 11
SP - e6883
JO - CLIN CASE REP
JF - CLIN CASE REP
SN - 2050-0904
IS - 1
ER -